Drugs / Glifage XR
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06560333 Comparator | Nov 2026 → Apr 2027 | type 2 diabetes mellitus | Eurofarma Laboratorios S.A. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glifage XR | “1 tablet of Forxiga® 10mg, 1 tablet of Januvia® 100mg and 1 tablet of Glifage XR® 1000mg” NCT06560333 ↗ |
| Route | Oral | “1 tablet of Glifage XR® 1000mg” NCT06560333 ↗ |